CPC215

CPC215 is a preclinical-stage small molecule drug candidate being developed by Alephoson for the treatment of non-infectious uveitis (NIU), including both anterior and posterior forms. The compound utilizes Alephoson's proprietary Cell-Penetrating Conjugate (CPC) platform, which is designed to enhance the delivery of therapeutic agents across biological barriers such as the blood-retinal barrier. By improving the penetration of the small molecule into ocular tissues, CPC215 aims to provide a more effective and potentially less invasive treatment option for inflammatory conditions of the eye. The specific biological target of the small molecule has not been publicly disclosed by the sponsor.